![Development and Validation of a Short Version of the Kansas City Cardiomyopathy Questionnaire. - Abstract - Europe PMC Development and Validation of a Short Version of the Kansas City Cardiomyopathy Questionnaire. - Abstract - Europe PMC](https://europepmc.org/articles/PMC4885562/bin/hcq-8-469-g003.jpg)
Development and Validation of a Short Version of the Kansas City Cardiomyopathy Questionnaire. - Abstract - Europe PMC
![Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF | JACC: Heart Failure Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF | JACC: Heart Failure](https://www.jacc.org/cms/asset/430c2937-838e-4761-9f46-854be6db67cf/gr4.jpg)
Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF | JACC: Heart Failure
![Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction | Circulation Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction | Circulation](https://www.ahajournals.org/cms/asset/f1651fa6-d545-4280-a2c6-cd4caedf8427/90fig04.gif)
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction | Circulation
![Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care: JACC State-of-the-Art Review - ScienceDirect Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care: JACC State-of-the-Art Review - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0735109720372326-gr1.jpg)
Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care: JACC State-of-the-Art Review - ScienceDirect
![Kansas City Cardiomyopathy Questionnaire Utility in Prediction of 30-Day Readmission Rate in Patients with Chronic Heart Failure Kansas City Cardiomyopathy Questionnaire Utility in Prediction of 30-Day Readmission Rate in Patients with Chronic Heart Failure](https://static.hindawi.com/articles/crp/volume-2016/4571201/figures/4571201.fig.001.jpg)
Kansas City Cardiomyopathy Questionnaire Utility in Prediction of 30-Day Readmission Rate in Patients with Chronic Heart Failure
![Development and Validation of a Short Version of the Kansas City Cardiomyopathy Questionnaire. - Abstract - Europe PMC Development and Validation of a Short Version of the Kansas City Cardiomyopathy Questionnaire. - Abstract - Europe PMC](https://europepmc.org/articles/PMC4885562/bin/hcq-8-469-g001.jpg)
Development and Validation of a Short Version of the Kansas City Cardiomyopathy Questionnaire. - Abstract - Europe PMC
![Psychometric properties of the Japanese version of the Kansas City Cardiomyopathy Questionnaire in Japanese patients with chronic heart failure | Health and Quality of Life Outcomes | Full Text Psychometric properties of the Japanese version of the Kansas City Cardiomyopathy Questionnaire in Japanese patients with chronic heart failure | Health and Quality of Life Outcomes | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12955-020-01483-0/MediaObjects/12955_2020_1483_Fig1_HTML.png)
Psychometric properties of the Japanese version of the Kansas City Cardiomyopathy Questionnaire in Japanese patients with chronic heart failure | Health and Quality of Life Outcomes | Full Text
![Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care: JACC State-of-the-Art Review - ScienceDirect Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care: JACC State-of-the-Art Review - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0735109720372326-gr2.jpg)
Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care: JACC State-of-the-Art Review - ScienceDirect
![Development and Validation of a Short Version of the Kansas City Cardiomyopathy Questionnaire. - Abstract - Europe PMC Development and Validation of a Short Version of the Kansas City Cardiomyopathy Questionnaire. - Abstract - Europe PMC](https://europepmc.org/articles/PMC4885562/bin/hcq-8-469-g006.jpg)